Projects per year
Projects 2007 2021
Active
Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)
6/27/19 → 6/30/21
Project: Other project
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX?23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y
Merck Sharp & Dohme Corporation
7/1/18 → 6/30/20
Project: Other project
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX?23 One Year Later in Healthy Adults 50 Years of Age or Older (PN
Merck Sharp & Dohme Corporation
6/11/18 → 6/10/20
Project: Other project
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35
Merck Sharp & Dohme Corporation
4/24/18 → 4/23/20
Project: Other project
Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized
Janssen Pharmaceutical Research & Develo
2/5/18 → 12/31/19
Project: Other project
A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Live-Attenuated Tetravalent Dengue Vaccine (V181) in Flavivirus-Naive and Flavivirus-Experienced Health Adults (MK-V181-001-01)
Merck Sharp & Dohme Corporation
1/4/18 → 1/3/20
Project: Other project
Completed
V503-010-0007: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 yea
Merck Sharp & Dohme Corporation
2/7/14 → 2/6/19
Project: Other project
Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"
Merck Sharp & Dohme Corporation
1/3/13 → 1/2/15
Project: Other project
Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)
Merck Sharp & Dohme Corporation
6/21/12 → 6/20/14
Project: Other project
Protocol: V114-002-008, "A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent
Merck Sharp & Dohme Corporation
3/1/12 → 6/14/19
Project: Other project
Novartis V59P13: A Phase III, Randomized, Ovserver-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to Healthy Adolescents 11-18 Years of Age and t
Novartis Pharmaceuticals Corporation
2/10/07 → 3/31/15
Project: Other project